Evidence map›Paper›PMID 39972983›Full record

ArticleBrain and behavior2025

Association of the Lipidome With Alzheimer's Disease and the Mediated Effect of Metabolites: A Two-Step Mendelian Randomization Study.

Yunfeng Yu, Juan Deng, Xinyu Yang, Jingyi Wu, Rong Yu, Chenlu Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yunfeng YuThe First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.ORCID https://orcid.org/0000-0002-7309-5608
Juan DengSchool of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Xinyu YangSchool of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Jingyi WuThe Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Rong YuSchool of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Chenlu GuoThe First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.

Funding

National Natural Science Foundation of China U21A20411the Hunan University of Chinese Medicine Disciplinary Construction' Revealing the List and Appointing Leaders' Project 22JBZ002
6 · The paper itself

Abstract

objectiveThis study aimed to explore the causal effects of lipidome on Alzheimer's disease (AD) and the mediated effects of the metabolites using Mendelian randomization (MR).

methodsData were obtained in genome-wide association studies, and single-nucleotide polymorphisms were screened according to the underlying assumptions of MR. Subsequently, weighted inverse variance was used to analyze the causality of lipidome with AD as well as the mediated effects of metabolites. Finally, MR-Egger, Cochran's Q, and sensitivity analysis were used to assess horizontal pleiotropy, heterogeneity, and robustness of the results, respectively.

resultsThe MR analysis showed that phosphatidylcholine (PC) (15:0_18:2) (mediated proportion: 18.30%, p = 0.024) and phosphatidylethanolamine (PE) (18:0_18:2) (mediated proportion: 14.60%, p = 0.028) mediated the reduction of AD risk by lowering betaine levels, which revealed lipidomic susceptibility. The MR-Egger intercept showed no horizontal pleiotropy for all results (p ≥ 0.05). Cochran's Q showed heterogeneity in some of the results. Sensitivity analysis indicated that all results were robust.

conclusionOur findings reveal the pathways through which PC (15:0_18:2) and PE (18:0_18:2) mediated the reduction of AD risk by lowering betaine levels.

Indexed as

Alzheimer DiseaseLipid MetabolismBetaineGenome-Wide Association StudyHumansLipidomicsMendelian Randomization AnalysisPhosphatidylcholinesPhosphatidylethanolaminesPolymorphism, Single NucleotideBetainePhosphatidylcholinesphosphatidylethanolaminePhosphatidylethanolaminesAlzheimer's diseaselipidomemediated effectMendelian randomizationmetabolites

Identifiers

PMID39972983
PMCPMC11839762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.